Arcturus Therapeutics 2024年第四季度GAAP每股收益$(1.11),不及预期$(0.44),销售额$22.800M,不及预期$44.650M

财报速递2025-03-07
Arcturus Therapeutics(NASDAQ:ARCT)报告季度亏损每股$(1.11),比分析师的共识预期$(0.44)低152.27%。这一数据比去年同期的每股亏损$(0.32)减少了246.88%。公司报告季度销售额为$22.800M,比分析师的共识预期$44.650M低48.94%。这一数据比去年同期的销售额$33.989M减少了32.92%。

以上内容来自Benzinga Earnings专栏,原文如下:

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.44) by 152.27 percent. This is a 246.88 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $22.800 million which missed the analyst consensus estimate of $44.650 million by 48.94 percent. This is a 32.92 percent decrease over sales of $33.989 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法